Phathom Pharmaceuticals (NASDAQ: PHAT) director exercises 8,750 options

Rhea-AI Filing Summary

Phathom Pharmaceuticals director Asit Parikh exercised stock options to acquire 8,750 shares of common stock. On 01/13/2026, he converted 8,750 derivative securities labeled as Common Stock (Right to Buy) at an exercise price of $10.30 per share into 8,750 shares of Phathom common stock in a transaction coded "M" (option exercise).

Following this transaction, Parikh directly beneficially owned 131,000 shares of Phathom Pharmaceuticals common stock. The filing does not show any sale of shares in connection with this option exercise; it simply reflects the option conversion and updated direct ownership.

Insider Trade Summary

8,750 shares exercised/converted

Mixed 2 txns

Insider Parikh Asit

Role Director

Type	Security	Shares	Price	Value
Exercise	Common Stock (Right to Buy)	8,750	$0.00	--
Exercise	Common Stock	8,750	$10.30	$90K

Holdings After Transaction: Common Stock (Right to Buy) — 0 shares (Direct); Common Stock — 131,000 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Asit

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		M		8,750	A	$10.3	131,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (Right to Buy)	$10.3	01/13/2026		M			8,750	05/23/2025	05/22/2034	Common Stock	8,750	$0	0	D

Explanation of Responses:

	/s/ Steven Basta, Attorney-in-Fact for Asit Parikh	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Phathom Pharmaceuticals (PHAT) report for Asit Parikh?

The company reported that director Asit Parikh exercised stock options, converting 8,750 derivative securities into 8,750 shares of common stock in a transaction coded "M" on 01/13/2026.

At what price were the Phathom Pharmaceuticals (PHAT) options exercised?

The options labeled as Common Stock (Right to Buy) were exercised at an exercise price of $10.30 per share, resulting in the acquisition of 8,750 shares of Phathom common stock.

How many Phathom Pharmaceuticals (PHAT) shares does Asit Parikh own after this Form 4 transaction?

After the reported option exercise, Asit Parikh directly beneficially owned 131,000 shares of Phathom Pharmaceuticals common stock, as shown in the Form 4 filing.

Did the Phathom Pharmaceuticals (PHAT) Form 4 show any sale of shares by Asit Parikh?

No. The reported transaction is coded "M" for an option exercise, showing acquisition of 8,750 shares of common stock and updated holdings, with no sale of common shares indicated.

What roles does Asit Parikh have at Phathom Pharmaceuticals (PHAT) according to this filing?

The Form 4 identifies Asit Parikh as a director of Phathom Pharmaceuticals and does not mark him as an officer or 10% owner in this report.